CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people with irreversible terminal heart failure. This concerns the sickest of the 20 million patients affected by this progressive disease in Europe and the United States. 2014 was an eventful year for the company, the publication of 2014 annual results of the company allows us to sum up the year performance:
Today, the CARMAT heart is a recognized as a leading project in Europe. The company with 47 employees enjoys the largest subsidy ever given to an SME by Bpifrance, an amount of €33M. No revenues were recorded by the company in 2014, the CARMAT total artificial heart still in clinical development and have not yet received CE marking (prior to commercialization in Europe). Net income at 31 December 2014 was €-18.3M against €-14.6M in 2013. However, during 2015, CARMAT should receive €2.2M research tax credit ( recorded at December 31, 2014) and €1.9M in grants and repayable advances under the contract with Bpifrance. Finally, CARMAT has secured its business development in early 2015 by the establishment of a new financing with the company Kepler Cheuvreux. All these financial resources should enable CARMAT to continue its clinical development and ensure the progress of its activities until 2016.
From a scientific point of view, the company was granted approval to resume the enrollment of patients within the framework of the first-in-man trial. The 2nd patient thus received a CARMAT heart in August, which allowed the Company to pass the halfway mark of this first-in-man trial by early September 2014. This patient left the hospital to return home early January 2015. In addition, the CARMAT artificial heart project has also been awarded several prizes:
- The “Mechatronics Award of the decade”, received in June 2014 at the European Mechatronics Meeting (EMM) in Annecy
- The “Prix d’honneur” honorary award from the Microns d’Or jury, received on September 23, 2014 at the Micronora international microtechnology trade fair in Besançon
- The 2014 INPI Award in the “Patent” category, received on December 2, 2014
In the beginning of the year 2015, the schedule of the company seems already complete:
- CARMAT has been selected in the EUnetHTA SEED program (the aim of this project is to initiate preliminary dialogue between Health Technology Assessment agencies and developers of new health products that are currently in the development stage before receiving CE marking)
- The company plans to initiate a second clinical trial on 20 to 25 patients, in France and / or abroad and to conduct additional preclinical validation.
Let's Continue The Conversation
Feel free to send us comments about this article to firstname.lastname@example.org and/or comment on that article on social media.